🔎 Trials Near Me

Akèy › Limfom › Illinois › Chicago

Etid klinik pou Limfom nan Chicago, IL

20 etid pou Limfom ap chèche patisipan nan sit nan ak bò kote Chicago (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Ap rekriteFaz 2
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07015242

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Ap rekriteFaz 1/2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
12 Months – 21 Years · Tout sèks · Mizajou Sep 11, 2026 · NCT04870944

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Ap rekriteFaz 1
  • University of Illinois Cancer Center, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06624085

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

Ap rekriteFaz 1/2
  • University of Chicago, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07284433

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Ap rekriteFaz 1/2
  • University of Chicago Medical Center, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04104776

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Ap rekriteFaz 1
  • The David and Etta Jonas Center for Cellular Therapy, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06528301

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Ap rekriteFaz 3
  • Northwestern, Chicago
  • University of Chicago, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07188558

Mosaic Trial for Stem Cell Transplant Recipients

Ap rekrite
  • Northwestern University Feinberg School of Medicine, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Aug 3, 2026 · NCT06960993

DALY II USA/ MB-CART2019.1 for DLBCL

Ap rekriteFaz 2
  • Robert H Lurie Cancer Center, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Ap rekriteFaz 1/2
  • Call for Information (Investigational Site 0024), Chicago
6 Months – 17 Years · Tout sèks · Mizajou Jul 6, 2026 · NCT02332668

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Ap rekriteFaz 1
  • Northwestern University, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT05131022

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Ap rekriteEtid obsèvasyon
  • Lurie Children's Hospital-Chicago, Chicago
Tout laj · Tout sèks · Mizajou May 18, 2026 · NCT01790152

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Ap rekriteFaz 1/2
  • Northwestern Memorial Hospital, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT03328078

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

Ap rekriteFaz 1/2
  • University of Illinois at Chicago Cancer Center, Chicago
Laj 12 a 95 · Tout sèks · Mizajou Apr 15, 2026 · NCT04329728

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Ap rekriteFaz 1
  • The University of Chicago Medical Center, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Mar 20, 2026 · NCT04830137

CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

Ap rekriteFaz 1/2
  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Mar 4, 2026 · NCT07294677

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

Ap rekrite
  • University of Chicago Comprehensive Cancer Center, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Feb 20, 2026 · NCT05745285

Avo In R/R And Previously Untreated MCL

Ap rekriteFaz 1/2
  • University of Chicago Medical Center, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Jan 21, 2026 · NCT04855695

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Ap rekriteFaz 1
  • Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2025 · NCT04234048

Etid Limfom nan lòt vil

Lòt etid nan Chicago

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.